Attovia Therapeutics, Inc.

Attovia Therapeutics, Inc. (ATTO) priced its initial public offering on Aug 5, 2026 at $17.00 per share, raising $289M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $731.5M. Fenwick & West advised the company and Cooley advised the underwriters.

Attovia Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. Its candidates include ATTO-1310, which is in the clinic, and ATTO-1091, a trispecific candidate.

Status

IPO

Ticker

ATTO

Exchange

Nasdaq Global Market

Priced

Aug 5, 2026

IPO price

$17.00

Raised

$289M

Market cap at IPO price

$731.5M

First filed

Jul 14, 2026

Company counsel

Fenwick & West

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.